SUPPRELIN LA Rx
Generic Name and Formulations:
Histrelin acetate 50mg; SC implant.
Indications for SUPPRELIN LA:
Treatment of central precocious puberty.
<2yrs: not recommended. ≥2yrs: Insert 1 implant SC in the inner aspect of the upper arm. Remove after 12 months; may replace. Consider discontinuing at appropriate time point for onset of puberty.
Use aseptic technique. Monitor for psychiatric symptoms. History of seizures/epilepsy, cerebrovascular disorders, CNS anomalies or tumors: risk of convulsions. Monitor LH, FSH, and estradiol or testosterone at 1 month post implantation, then every 6 months thereafter. Assess height and bone age every 6–12 months.
May interfere with pituitary gonadotropic and gonadal function tests. Caution with concomitant drugs that are associated with convulsions (eg, bupropion, SSRIs).
Implant site reactions (eg, bruising, pain, soreness, erythema, swelling), initial worsening of signs/symptoms.
Kit—1 (w. implant and insertion tool)
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Undifferentiated Headaches Common in Children, Adolescents
- Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS
- Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life
- No Reduction in Cerebral Perfusion With Intensive Blood Pressure Lowering
- Successful Delirium Prevention in Critically Ill With Dexmedetomidine